企業プロフィール
Innate Pharma 株価・ニュース・カタリスト
- ティッカー:
- IPHA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- France
株価パフォーマンス
2.26 USD (+8.13%)
終値
最終更新: 2026年8月21日
171M USD
時価総額
株価変動の要因
As of Aug 21, 2026, IPHA closed up 8.13% at $2.26. No new same-company headline was identified in the current news window.
企業概要
Innate Immunity Oncology Company
Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer.
Lacutamab
Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma.
ADC and Partnered Pipeline
IPH4502 is a Nectin-4 ADC, while partnered programs include monalizumab and anti-CD39 antibody IPH5201 with AstraZeneca.
今後のカタリスト
- Initiation of the confirmatory Phase 3 TELLOMAK-3 study of lacutamab is planned for the second half of 2026, subject to securing non-dilutive financing.
- Phase 3 PACIFIC-9 data for the monalizumab-containing regimen are planned for the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。